TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier

As the first in a new class of non-opioid drugs, ω-Conotoxin MVIIA was approved for the management of severe chronic pains in patients who are unresponsive to opioid therapy. Unfortunately, clinical application of MVIIA is severely limited due to its poor ability to penetrate the blood-brain ba...

Full description

Bibliographic Details

Main Authors:	Shuo Yu, Yumeng Li, Jinqin Chen, Yue Zhang, Xinling Tao, Qiuyun Dai, Yutian Wang, Shupeng Li, Mingxin Dong
Format:	Artigo
Language:	Inglês
Published:	MDPI AG 2019-05-01
Series:	Marine Drugs
Subjects:	ziconotide TAT (the transactivator of transcription domain) peptide analgesics BBB (blood-brain barrier) penetration
Online Access:	https://www.mdpi.com/1660-3397/17/5/286
Tags:	Add Tag No Tags, Be the first to tag this record!